Anti-GCLC Antibody, clone 2H13 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2H13 is a ZooMAb^® recombinant rabbit monoclonal antibody that detects GCLC. It targets an epitope within 24 amino acids from the N-terminal half.

KLH-conjugated linear peptide corresponding to 24 amino acids from the N-terminal half of human GCLC.

Quality Control Testing

Evaluated by Western Blotting in A549 cell lysate.

Western Blotting Analysis (WB): A 1:1,000 dilution of this antibody detected GCLC protein in A549 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000-10,000 dilution from a representative lot detected GCLC in HepG2, NIH/3T3, and C6 cell lysates.

Affinity Binding Assay: A representative lot of this antibody bound GCLC peptide with at least ten thousand-fold (10,000X) higher than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected GCLC in human kidney tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected GCLC in A-431 and A549 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Glutamate-cysteine ligase catalytic subunit (UniProt: P48506; EC:6.3.2.2; also known as GCS heavy chain, Gamma-ECS, Gamma-glutamylcysteine synthetase) is encoded by the GCLC (also known as GLCL, GLCLC) gene (Gene ID: 2729) in human. The glutamate-cysteine ligase catalytic subunit (GCLC) is part of the glutamate-cysteine ligase (GCL) enzyme, which also includes a modifier subunit (GCLM). GCLC contains the active site of the enzyme and is primarily responsible for its enzymatic activity. Structurally, GCLC features several domains critical for substrate binding and catalysis, and it functions optimally when associated with GCLM, which enhances the enzyme′s activity and stability. GCLC is crucial for the synthesis of glutathione, a major antioxidant in cells. It catalyzes the first and rate-limiting step of glutathione synthesis, which involves the formation of gamma-glutamylcysteine from glutamate and cysteine. This process is vital for maintaining cellular redox homeostasis, detoxifying harmful substances, and modulating cell signaling and proliferation. GCLC is expressed ubiquitously across various tissues, with higher levels observed in organs that are involved in detoxification processes, such as the liver and kidneys. Its expression can be upregulated in response to oxidative stress, toxins, and other factors that increase the cellular demand for glutathione. Decreased GCLC activity can lead to reduced glutathione levels, contributing to oxidative stress and cellular damage. This mechanism is relevant in various pathologies, including neurodegenerative diseases like Alzheimer′s and Parkinson′s disease, where oxidative stress is a significant contributing factor. Additionally, GCLC dysregulation has been implicated in cancer, cardiovascular diseases, and conditions like diabetes, where impaired antioxidant defenses exacerbate disease progression.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.